New Born Babies Antibodies

Banaras Hindu University (BHU) scientists have developed a new variety of medicinal plant Rishyagandha which has the properties to treat all types of cancer, especially cervical. After eight years of long research, the new variety was developed using nano-biotechnology. The research done on the basis of Indian Ayurveda is now being approved by scientists of many countries. Rishyagandha is mainly available in the dry hot climatic conditions of Afghanistan, Pakistan and India. Rishyagandha is commonly known as 'Paneer flower' or 'Paneer bandha' and in scientific language as 'Withania coagulans'. Generally, its seeds are used for making paneer in dairy industry, as it has enzyme protease. Studies related to these findings have been published in the prestigious international research journals such as 'Material Science and Engineering C', 'Plant Cell Reports' and 'Physiology and Molecular Biology of Plants'. The plant has been included into endangered category due to indiscriminate use and various other reasons. Currently, to maintain the sustainability of this endangered plant and to improve the pharmacological efficiency with high efficacy, various researches are being carried out. Prof. Shashi Pandey from Department of Botany, BHU told IANS, "scientists at Banaras Hindu University have grown high quality medicinal plant Rishyagandha in their lab by uitlising nano-biotechnological approach. This is a latest example of integrating technology in Ayurveda research and taking the ancient medical science of India to the masses." Prof. Shashi Pandey undertook a research with her student Dr. Deepika Tripathi eight years ago. The study of Dr. Pandey suggested the potential role of Nano-biotechnology in the improvised version of Rhishygandha along with the high content of bioactive pharmacological compounds withanolides. Prof. Pandey said that initially they developed an efficient protocol to propagate this endangered plant using in-vitro plant tissue culture methods. Further, under collaboration with Prof. Gopeshwar Narayan of Molecular and Human Genetics Department, efficiency of green synthesised nanoparticles were also studied using laboratory grown plant extracts as a potent drug against cervical cancer. Continuing this research work, Prof. Pandey found that synthesised nanoparticles and UV-B treatment in the laboratory conditions enhanced the yield of Rishyagandha with a quantitative increase of about 50 per cent in its medicinally useful compounds withanolides. Prof. Pandey told IANS: "By integrating nano-biotechnological approaches, we can conserve the plant in nature along with its enhanced medicinal potential. New researchers of lab are now extending this work towards finding out the effect of different exnvironment factors on the production of the compounds Rishyagandha." Recognising Pandey's effort, recently she has been elected as a member of Genome India International (GII). "Banaras Hindu University offers a unique amalgamation of education and research in traditional Indian knowledge and modern sciences at one place. This specialty makes BHU truly the capital of knowledge, not only in India but all across the globe," Prof. Pandey added. (agency) Read More► BHU to Conduct Research on Economical Anti-Diabetic Drugs

टोक्यो: स्वास्थ्य विशेषज्ञों ने इस बात पर चिंता व्यक्त की है कि ओमीक्रॉन के संक्रमण के मामलों को घटता देखकर जब दुनिया भर से प्रतिबंधों को हटाया जा रहा है, वैसी स्थिति में ओमीक्रॉन का नया वैरिएंट बीए.2 संक्रमण और मौत के मामलों में अचानक बहुत तेजी ला सकता है। एपिडेमोलॉजिस्ट एरिक फिल डिंग भी इस बात की पुष्टि करते हुए कहते हैं कि ओमीक्रॉन का नया वैरिएंट निश्चित रूप से बुरी खबर है। एरिक ने बताया है कि विश्व स्वास्थ्य संगठन भी इस बात को लेकर बहुत चिंतित है कि यह वैरिएंट पुराने ओमीक्रॉन की तुलना में अधिक संक्रामक और गंभीर है। उन्होंने बताया कि डेनमार्क में कोरोना संक्रमण के जितने नये मामले सामने आये हैं, उनमें से 90 फीसदी मामले ओमीक्रॉन के बीए.2 वैरिएंट के हैं और इसका स्वास्थ्य पर बहुत गंभीर प्रभाव देखने को मिल रहा है। एरिक ने कहा कि डेनमार्क में कई सप्ताह से बीए.2 वैरिएंट सक्रिय है और अब वहां मौत के मामले बढ़ रहे हैं। डेनमार्क के स्वास्स्थ्य अधिकारियों ने प्रारंभिक आंकड़ो के आधार पर पहले कहा था कि नया वैरिएंट बीए.1 की तुलना में डेढ़ गुणा अधिक संक्रामक है लेकिन इसका असर उतना गंभीर नहीं होता है। विश्व स्वास्थ्य संगठन में कोविड-19 के मामलों की तकनीक प्रमुख मारिया वान केरखोव ने भी कहा है कि बीए.2 वैरिएंट ओमीक्रॉन के पुराने वैरिएंट से अधिक संक्रामक है और इसके प्रसार को रोकने की जरूरत है। उन्होंने चेतावनी देते हुए कहा कि अगर ऐसा नहीं हुआ तो इससे सिर्फ कोरोना संक्रमण के मामले ही नहीं बढ़ेंगे बल्कि हम अस्पताल में भर्ती होने और मौत के मामलों में भी तेजी देखेंगे। हम यह भी देखेंगे कि लोग लॉंग कोविड से ग्रसित हैं और साथ ही कोरोना वायरस के नये वैरिएंट को भी पनपने का मौका मिल रहा है। टोक्यो यूनिवर्सिटी द्वारा किये गये शोध से यह बात सामने आयी है कि यूरोप और एशिया के कई देशों में ओमीक्रॉन का नया वैरिएंट तेजी से फैल रहा है। शोध के मुताबिक वैश्विक स्वास्थ्य के लिए यह अब तक का सबसे चिंताजनक वैरिएंट हो सकता है। वर्तमान में दोनों वैरिएंट को ओमीक्रॉन के नाम से जाना जा रहा है और इनमें अंतर करना बहुत मुश्किल है। शोधकर्ता काई सातो ने कहा कि शोध के आधार पर हम यह प्रस्ताव पेश करते हैं कि नये वैरिएंट को अलग वैरिएंट के रूप में मान्यता दी जाये और इसके बारे में गहराई से निगरानी की जाये। (एजेंसी) यह भी पढ़े► कोविड के कण 200 फीट की दूरी पर भी संक्रमित कर सकते हैं: स्टडी

Jerusalem: According to a new study, although over time the number of SARS-CoV-2 antibodies fall in both previously infected and vaccinated patients, the performance of antibodies improve only after the previous infection. The researchers, including Carmit Cohen of the Sheba Medical Center, indicated that while protection against re-infection lasts for a long time in SARS-CoV-2 recovered patients, breakthrough infections are increasingly common six months after vaccination. "While the number of antibodies decrease with time in both Covid-19 recovered (but never vaccinated) patients and vaccinated (but never infected) individuals, the quality of antibodies increases the following infection but not after vaccination," the researchers said. The study also found that, contrary to expectations, previously infected patients with obesity had a higher and more sustained immune response than overweight and normal weight range patients. For the study, to be presented at this year's European Congress of Clinical Microbiology and Infectious Diseases, the team analysed the humoral (antibody-induced) immune response in Covid-19 recovered but unvaccinated individuals for up to a year and compared it with those who had received two doses of the Pfizer vaccine (but no previous infection) over eight months. The study recruited previously infected-unvaccinated and double vaccinated never infected individuals from March 25 to November 25 2020 and closed in April 2021, just before the Delta variant arrived in Israel. The researchers followed up on 130 patients diagnosed with SARS-COV-2 using PCR testing. These patients had not been vaccinated and remained unvaccinated during the study. None of these patients were reinfected during the study period. (Agency) Read More► Post-Vax Exercise Bumps Up Antibodies: Study

New York: Around 90 minutes of mild-to moderate-intensity exercise directly after the flu or the Covid-19 vaccine may provide an extra immune boost, suggests a new study. The study showed that participants who cycled on a stationary bike or took a brisk walk for an hour-and-a-half after getting a jab produced more antibodies in the following four weeks compared to participants who sat or continued with their daily routine post-immunization. The researchers, including lead author Marian Kohut from Iowa State University, found similar results when they ran an experiment with mice and treadmills. "Our preliminary results are the first to demonstrate a specific amount of time can enhance the body's antibody response to the Pfizer-BioNTech Covid-19 vaccine and two vaccines for influenza," said Kohut. The researchers said the study's findings could directly benefit people with a range of fitness levels. Nearly half of the participants in the study, published in the journal Brain, Behavior and Immunity, had a BMI in the overweight or obese category. During 90 minutes of exercise, they focused on maintaining a pace that kept their heart rate around 120-140 beats per minute rather than distance. In the study, the researchers also tested whether participants could get the same bump in antibodies with just 45-minutes of exercising. They found the shorter workout did not increase the participants' antibody levels. As to why prolonged, mild-to moderate-intensity exercise could improve the body's immune response, Kohut said there may be multiple reasons. Working out increases blood and lymph flow, which helps circulate immune cells. As these cells move around the body, they're more likely to detect something foreign, the researcher said. (agency) Read More► Role of Vitamin D in Covid-19